Leland Stanford Junior University

Rapt Therapeutics, Inc.

Siteone Therapeutics, Inc.

Grant Masaaki Shibuya

George P Miljanich

David Juergen Wustrow

Justin Du Bois

John Mulcahy

Hassan Pajouhesh

Anton Delwig

Mikhail Zibinsky

Jeffrey J Jackson

Dennis X Hu

Paul Robert Leger

Jacob Beckley

Jacob Bradley Schwarz

Jack Maung

Anton Shakhmin

Akinori Okano

Omar Robles

Xinping Han

Adrian O Dukes

Anqi Ma

Andrew A Ng

Cyril Bucher

Michelle Yoo Min Ko

Hunter Paul Shunatona

John Michael Ketcham

Parcharee Tivitmahaisoon

Ashkaan Younai

Berenger Biannic

Kyle Young

Daniel Poon

Vi-Anh Vu

Blanca Gomez

James P Davidson

Minna H T Bui

Yoo Min Ko

Hannah Haley

Justin Dubois

Disclosed herein are methods of synthesis of a trans isomeric form of a C—C chemokine receptor type 4 (CCR4) modulator, or a salt or ester thereof that comprise making a trans isomeric compound of formula (III) by reacting a compound of formula (I) with a compound of formula (II) in the presence of a carboxylic acid directed reducing agent, wherein the compound of formula (III) is in a predominantly trans isomerically pure form.

Methods of making trans isomeric forms of G protein-coupled receptor modulators

Disclosed herein are pyrazole pyrimidine compounds that modulate and/or inhibit hematopoietic progenitor kinase 1, as well as methods of making such compounds and therapeutic methods of using same.

Pyrazole pyrimidine compounds and uses thereof

Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R, R, R, R, and Xare as described herein.

11,13-modified saxitoxins for the treatment of pain

Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R, X, and Xare as described herein. 

Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R, R, R, R, and Xare as described herein. 

Disclosed herein are pyrozolo-pyrimidin-amino-cycloalkyl compounds, analogs thereof, pharmaceutical compositions comprising thereof and therapeutic uses therefor.

Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses

Disclosed herein, inter alia, compounds and methods of use thereof for the modulation of USP7 activity.

Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof

Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R, Xand Xare as described herein.

Growing community of inventors

South San Francisco, CA, United States of America

Grant Masaaki Shibuya